Your browser doesn't support javascript.
loading
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting ß1 Selective Antagonist) in Atrial Fibrillation.
Floria, Mariana; Oancea, Alexandru Florinel; Morariu, Paula Cristina; Burlacu, Alexandru; Iov, Diana Elena; Chiriac, Cristina Petronela; Baroi, Genoveva Livia; Stafie, Celina Silvia; Cuciureanu, Magdalena; Scripcariu, Viorel; Tanase, Daniela Maria.
Afiliación
  • Floria M; Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Oancea AF; Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
  • Morariu PC; Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Burlacu A; Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
  • Iov DE; Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Chiriac CP; Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
  • Baroi GL; Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Stafie CS; Cardiovascular Disease Institute, 700503 Iasi, Romania.
  • Cuciureanu M; Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Scripcariu V; Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
  • Tanase DM; Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
Pharmaceutics ; 16(4)2024 Apr 08.
Article en En | MEDLINE | ID: mdl-38675178
ABSTRACT
Landiolol is an ultra-short-acting, selective ß1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high ß1-selectivity, potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half-life (around 4 min); moreover, it may have a potential therapeutic effects for sepsis and pediatric patients. Landiolol seems to be superior to other short-acting and selective beta-blockers such as esmolol. This review aims to provide a comprehensive overview of landiolol, a new ultra-short-acting ß1 selective antagonist, including its pharmacology, clinical applications, efficacy, safety profile, and future directions in research and clinical data.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza